Karuna: Bristol Myers Squibb completes acquisition of Karuna Therapeutics
KarXT, Karuna's lead asset, is a potential first-in-class treatment for Schizophrenia
Read full article »
Karuna is a Massachusetts-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for the treatment of mental illnesses.
Read more